Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm’s EPO product gains exclusive contract for 19 Chinese military hospitals in Q2.
You may also be interested in...
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
Projected U.S. approval triggers Chinese NDA for the anemia drug.
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
Projected U.S. approval triggers Chinese NDA for the anemia drug.
Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu
Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.